Am J Cardiovasc Drugs (2018) 18:143–151 https://doi.org/10.1007/s40256-018-0264-5 SHORT COMMUNICATION Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic 1 1 Elizabeth K. Pogge Lindsay E. Davis Published online: 17 February 2018 Springer International Publishing AG, part of Springer Nature 2018 Abstract blood pressure of 6 mmHg with no signiﬁcant changes in Objective The objective of this research was to describe serum creatinine, blood urea nitrogen, or potassium levels. the use of pharmacist-managed sacubitril/valsartan therapy Conclusions With close monitoring and follow-up, ARNi in a multi-center, outpatient cardiac group. therapy was a safe alternative to ACEi/ARB therapy for Background Sacubitril/valsartan, an angiotensin receptor- chronic symptomatic HFrEF when initiated within a neprilysin inhibitor (ARNi), is a novel agent for the treat- pharmacist clinic. ment of heart failure. An ARNi is recommended by national guidelines to be used in place of angiotensin- Abbreviations ACEi Angiotensin-converting enzyme converting enzyme inhibitor (ACEi) or angiotensin recep- tor blocker (ARB) therapy for patients who remain inhibitor AHA American Heart Association symptomatic. Methods A retrospective chart review was performed to ARB Angiotensin receptor blocker identify patients initiated and fully titrated on sacubi- ARNi Angiotensin receptor-neprilysin tril/valsartan therapy from July 7, 2015 to March
American Journal of Cardiovascular Drugs – Springer Journals
Published: Feb 17, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera